Drug that cuts breast cancer risk set for wider use in UK

Drug that can halve breast cancer risk offered to 289,000 women in England

FDA approves the first treatment for nasopharyngeal carcinoma, a rare cancer that originates in the nasopharynx. The drug (toripalimab-tpzi) is a next-generation, programmed death receptor-1 monoclonal antibody. Because of the tumor's location (behind the nose), surgery is not usually an option.

Scientists Investigating Alzheimer’s Drug Faulted in Leaked Report